[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 7 of about 7
1. Ray-Coquard I, Ghesquière H, Bachelot T, Borg C, Biron P, Sebban C, LeCesne A, Chauvin F, Blay JY, ELYPSE Study Group: Identification of patients at risk for early death after conventional chemotherapy in solid tumours and lymphomas. Br J Cancer; 2001 Sep 14;85(6):816-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The model was delineated in a series of 1051 cancer patients receiving a first course of chemotherapy in the Department of Medicine of the Centre Léon Bérard (CLB) in 1996 (CLB-1996 cohort), and then validated in a series of patients treated in the same department in 1997 (CLB-1997), in a prospective cohort of patients with aggressive non-Hodgkin's lymphoma (NHL) (CLB-NHL), and in a prospective cohort of patients with metastatic breast cancer (MBC series) receiving first-line chemotherapy.
  • In univariate analysis, age > 60, PS > 1, lymphocyte (ly) count <or= 700 microl(-1)immediately prior to chemotherapy (d1), d1-platelet count <or= 150 Gl(-1), and the type of chemotherapy were significantly correlated to the risk of early death (P<or= 0.01).
  • In the CLB-97, CLB-NHL and MBC validation series, the observed incidences of early death in patients with both risk factors were 19%, 25% and 40% respectively and did not differ significantly from those calculated in the model.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Lymphoma / mortality. Neoplasms / mortality
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Cohort Studies. Female. France / epidemiology. Humans. Incidence. Male. Middle Aged. Prognosis. Retrospective Studies. Risk Factors. Survival Rate

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Cancer Research Campaign http://www.bjcancer.com.
  • [Cites] Drugs Aging. 1997 Jan;10(1):34-49 [9111706.001]
  • [Cites] Cancer Res. 1996 Dec 1;56(23):5499-505 [8968107.001]
  • [Cites] J Clin Oncol. 1998 Jun;16(6):2065-9 [9626205.001]
  • [Cites] Blood. 1998 Jul 15;92(2):405-10 [9657738.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2840-6 [10561360.001]
  • [Cites] Clin Cancer Res. 2000 Apr;6(4):1351-64 [10778963.001]
  • [Cites] Nat Med. 2000 May;6(5):493-5 [10802692.001]
  • [Cites] Cancer. 1970 Jan;25(1):135-40 [5410303.001]
  • [Cites] Curr Concepts Nutr. 1977;6:7-13 [604019.001]
  • [Cites] JAMA. 1979 Aug 17;242(7):623-32 [449002.001]
  • [Cites] Surg Clin North Am. 1981 Jun;61(3):437-63 [7020129.001]
  • [Cites] Eur J Cancer Clin Oncol. 1984 Jan;20(1):55-60 [6537916.001]
  • [Cites] Br J Cancer. 1989 May;59(5):801-4 [2544222.001]
  • [Cites] Bull Cancer. 1990;77(9):941-7 [2224167.001]
  • [Cites] Cancer. 1991 Feb 1;67(3):716-21 [1985764.001]
  • [Cites] N Engl J Med. 1993 Apr 8;328(14):1002-6 [7680764.001]
  • [Cites] J Clin Oncol. 1993 Jul;11(7):1276-85 [8315425.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14):987-94 [8141877.001]
  • [Cites] Lung Cancer. 1993 Dec;10(3-4):189-97 [8075966.001]
  • [Cites] Nat Med. 1996 Mar;2(3):317-22 [8612231.001]
  • [Cites] J Clin Oncol. 1996 Feb;14(2):636-43 [8636781.001]
  • [Cites] Nat Med. 1996 Dec;2(12):1361-6 [8946836.001]
  • [Cites] Cancer. 1998 Jan 1;82(1):116-26 [9428487.001]
  • (PMID = 11556830.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ PMC2375083
  •  go-up   go-down


2. Postema EJ, McEwan AJ, Riauka TA, Kumar P, Richmond DA, Abrams DN, Wiebe LI: Initial results of hypoxia imaging using 1-alpha-D: -(5-deoxy-5-[18F]-fluoroarabinofuranosyl)-2-nitroimidazole ( 18F-FAZA). Eur J Nucl Med Mol Imaging; 2009 Oct;36(10):1565-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The safety and general biodistribution patterns of this radiopharmaceutical in patients with squamous cell carcinoma of the head and neck (HNSCC), small-cell lung cancer (SCLC) or non-small-cell lung cancer (NSCLC), malignant lymphoma, and high-grade gliomas, were demonstrated in this study.
  • METHODS: Patients with known primary or suspected metastatic HNSCC, SCLC or NSCLC, malignant lymphoma or high-grade gliomas were dosed with 5.2 MBq/kg of (18)F-FAZA, then scanned 2-3 h after injection using a PET or PET/CT scanner.
  • Images were interpreted by three experienced nuclear medicine physicians.
  • Of the 21 lymphoma patients (15 with non-Hodgkin's lymphoma and 6 with Hodgkin's disease), 3 demonstrated moderate lymphoma-related uptake.
  • Given the good imaging properties, including acceptable T/B ratios in the tumour categories studied, (18)F-FAZA could be considered as a very promising agent for assessing the hypoxic fraction of these tumour types.
  • [MeSH-major] Hypoxia / diagnostic imaging. Neoplasms / diagnostic imaging. Nitroimidazoles. Radiopharmaceuticals
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Non-Small-Cell Lung / diagnostic imaging. Carcinoma, Small Cell / diagnostic imaging. Carcinoma, Squamous Cell / diagnostic imaging. Female. Fluorine Radioisotopes. Glioma / diagnostic imaging. Head and Neck Neoplasms / diagnostic imaging. Humans. Lung Neoplasms / diagnostic imaging. Lymphoma / diagnostic imaging. Male. Middle Aged. Positron-Emission Tomography. Young Adult

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiother Oncol. 1993 Jan;26(1):45-50 [8438086.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10 (24):8177-84 [15623592.001]
  • [Cites] J Nucl Med. 2005 Jan;46(1):106-13 [15632040.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2005 Dec;32(12 ):1384-91 [16133382.001]
  • [Cites] J Nucl Med. 2004 Nov;45(11):1851-9 [15534054.001]
  • [Cites] J Nucl Med. 2008 Feb;49(2):201-5 [18199612.001]
  • [Cites] Radiat Res. 2008 Dec;170(6):677-90 [19138031.001]
  • [Cites] Radiother Oncol. 1991;20 Suppl 1:13-9 [2020762.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Oct 1;69(2):541-51 [17869667.001]
  • [Cites] AJR Am J Roentgenol. 2008 Feb;190(2):427-32 [18212229.001]
  • [Cites] J Nucl Med. 2006 Mar;47(3):410-8 [16513609.001]
  • [Cites] J Natl Cancer Inst. 2001 Feb 21;93(4):266-76 [11181773.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2007 Oct;34(10 ):1566-75 [17447061.001]
  • [Cites] J Clin Oncol. 2006 May 1;24(13):2098-104 [16648512.001]
  • [Cites] J Am Geriatr Soc. 2007 Jul;55(7):1142-4 [17608896.001]
  • [Cites] J Nucl Med. 1992 Dec;33(12 ):2133-7 [1334136.001]
  • [Cites] J Nucl Med. 2006 Dec;47(12 ):1921-6 [17138734.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 May 1;38(2):285-9 [9226314.001]
  • [Cites] Q J Nucl Med. 1996 Sep;40(3):270-84 [8961804.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Jul 1;35(4):701-8 [8690636.001]
  • [Cites] Acta Oncol. 2000;39(5):629-37 [11093372.001]
  • [Cites] Nucl Med Biol. 2003 Apr;30(3):317-26 [12745023.001]
  • [Cites] Clin Cancer Res. 2008 May 1;14 (9):2623-30 [18451225.001]
  • [Cites] Radiat Res. 1980 Apr;82(1):171-90 [7367588.001]
  • [Cites] Br J Cancer Suppl. 1996 Jul;27:S209-12 [8763882.001]
  • [Cites] Semin Nucl Med. 2007 Nov;37(6):451-61 [17920352.001]
  • (PMID = 19430784.001).
  • [ISSN] 1619-7089
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Fluorine Radioisotopes; 0 / Nitroimidazoles; 0 / Radiopharmaceuticals; 0 / fluoroazomycin arabinoside
  •  go-up   go-down


3. Dragovich T, Gordon M, Mendelson D, Wong L, Modiano M, Chow HH, Samulitis B, O'Day S, Grenier K, Hersh E, Dorr R: Phase I trial of imexon in patients with advanced malignancy. J Clin Oncol; 2007 May 1;25(13):1779-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The drug induces apoptosis through accumulation of reactive oxygen species.
  • PATIENTS AND METHODS: Forty-nine patients with metastatic cancer received intravenous imexon over 30 to 45 minutes for 5 consecutive days (one course) every other week (days 1 through 5 and 15 through 19) monthly.
  • Other common toxicities included nausea and vomiting (58%) and constipation (63%); both were managed well with prophylactic medications.
  • One partial response was obtained in a heavily pretreated patient with non-Hodgkin's lymphoma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Hexanones / therapeutic use. Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Area Under Curve. Female. Half-Life. Humans. Infusions, Intravenous. Male. Maximum Tolerated Dose. Middle Aged

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17470869.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-17094
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Hexanones; 59643-91-3 / 4-imino-1,3-diazabicyclo(3.1.0)hexan-2-one
  •  go-up   go-down


Advertisement
4. Saikia UN, Dey P, Jindal B, Saikia B: Fine needle aspiration cytology in lymphadenopathy of HIV-positive cases. Acta Cytol; 2001 Jul-Aug;45(4):589-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All these patients were heterosexual, and none had a history of drug abuse.
  • There was one case each diagnosed as non-Hodgkin's lymphoma and squamous cell carcinoma (metastatic).
  • [MeSH-minor] Adolescent. Adult. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / pathology. Female. Histocytological Preparation Techniques / methods. Humans. Lymphoma, AIDS-Related / diagnosis. Lymphoma, AIDS-Related / pathology. Male. Tuberculosis, Lymph Node / diagnosis. Tuberculosis, Lymph Node / pathology


5. Doolittle ND, Anderson CP, Bleyer WA, Cairncross JG, Cloughesy T, Eck SL, Guastadisegni P, Hall WA, Muldoon LL, Patel SJ, Peereboom D, Siegal T, Neuwelt EA: Importance of dose intensity in neuro-oncology clinical trials: summary report of the Sixth Annual Meeting of the Blood-Brain Barrier Disruption Consortium. Neuro Oncol; 2001 01;3(1):46-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This report summarizes the discussions, future directions, and key questions regarding dose-intensive treatment of primary CNS lymphoma, CNS relapse of systemic non-Hodgkin's lymphoma, anaplastic oligodendroglioma, high-grade glioma, and metastatic cancer of the brain.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Blood-Brain Barrier / drug effects. Brain Neoplasms / drug therapy. Hypertonic Solutions / pharmacology. Meningeal Neoplasms / drug therapy
  • [MeSH-minor] Adult. Animals. Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Agents, Alkylating / adverse effects. Antineoplastic Agents, Alkylating / pharmacokinetics. Antineoplastic Agents, Alkylating / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / pharmacokinetics. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow Diseases / chemically induced. Bone Marrow Transplantation. Buthionine Sulfoximine / pharmacology. Buthionine Sulfoximine / therapeutic use. Child. Clinical Trials as Topic / methods. Clinical Trials, Phase III as Topic. Cognition Disorders / etiology. Combined Modality Therapy. Cranial Irradiation. Dose-Response Relationship, Drug. Drug Synergism. Genetic Therapy. Genetic Vectors / pharmacokinetics. Glioma / drug therapy. Glioma / metabolism. Glutathione / metabolism. Guinea Pigs. Hearing Loss, Sensorineural / chemically induced. Hearing Loss, Sensorineural / prevention & control. Hematopoietic Stem Cell Transplantation. Humans. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / pathology. Multicenter Studies as Topic / methods. Neuroblastoma / drug therapy. Oligodendroglioma / drug therapy. Permeability / drug effects. Quality of Life. Randomized Controlled Trials as Topic / methods. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11305417.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1R13 CA 86959-01
  • [Publication-type] Congresses; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Alkylating; 0 / Hypertonic Solutions; 5072-26-4 / Buthionine Sulfoximine; GAN16C9B8O / Glutathione
  • [Other-IDs] NLM/ PMC1920598
  •  go-up   go-down


6. Gow KW, Lensing S, Hill DA, Krasin MJ, McCarville MB, Rai SN, Zacher M, Spunt SL, Strickland DK, Hudson MM: Thyroid carcinoma presenting in childhood or after treatment of childhood malignancies: An institutional experience and review of the literature. J Pediatr Surg; 2003 Nov;38(11):1574-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Three of the 8 (37.5%) had metastatic disease involving regional lymph nodes; 2 patients (25.0%) had lung metastases.
  • Six patients required radioactive iodine (I 131) ablation for residual or metastatic disease after surgical resection.
  • Seventeen patients had thyroid carcinoma as a second malignant neoplasm after treatment for acute lymphoblastic leukemia (n = 6), Hodgkin's disease (n = 5), central nervous system tumor (n = 2), Wilms' tumor (n = 1), retinoblastoma (n = 1), non-Hodgkin's lymphoma (n = 1), or neuroblastoma (n = 1).
  • Four patients (23.5%) had metastatic disease involving regional lymph nodes.
  • Six patients (35.3%) required I(131) ablation for residual or metastatic disease after thyroidectomy.
  • [MeSH-minor] Adolescent. Adult. Child. Cohort Studies. Combined Modality Therapy. Female. Humans. Iodine Radioisotopes / therapeutic use. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Neoplasms / drug therapy. Neoplasms / radiotherapy. Neoplasms, Radiation-Induced / epidemiology. Retrospective Studies. Tennessee / epidemiology. Thyroidectomy. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14614703.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 21765
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iodine Radioisotopes
  • [Number-of-references] 49
  •  go-up   go-down


7. Paydas S, Ergin M, Baslamisli F, Yavuz S, Zorludemir S, Sahin B, Bolat FA: Bone marrow necrosis: clinicopathologic analysis of 20 cases and review of the literature. Am J Hematol; 2002 Aug;70(4):300-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Among the malignant cases, three cases had acute myeloblastic leukemia (AML), four had relapsed Hodgkin's disease (R-HD), one had acute lymphoblastic leukemia (ALL), two had chronic myelocytic leukemia (CML), two had non-Hodgkin's lymphoma (NHL), three had disseminated intravascular coagulation (DIC) associated with metastatic solid tumor, and one had myelodysplastic syndrome/myeloproliferative syndrome (MDS/MPS).
  • Among the nonmalignant cases, two had tuberculosis infection, one had anti-phospholipid syndrome (APS), and one had a history of drug ingestion.
  • [MeSH-minor] Adolescent. Adult. Aged. Bone Marrow Diseases / diagnosis. Bone Marrow Diseases / etiology. Bone Marrow Diseases / pathology. Female. Hematologic Diseases / diagnosis. Hematologic Diseases / pathology. Hematologic Neoplasms / diagnosis. Hematologic Neoplasms / pathology. Humans. Leukemic Infiltration. Male. Middle Aged. Necrosis. Retrospective Studies






Advertisement